Biotech

All Articles

A more detailed look at Ferocious Biotech's Tough 15

.Within this full week's episode of "The Top Pipe," our team are actually diving right into Ferociou...

Lilly faces period 2 breakdown of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's party celebrating the commendation o...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of considerable management hirings, shootings as...

Lykos will certainly talk to FDA to reconsider its own choice adhering to denial of MDMA treatment for trauma

.Observing a bad showing for Lykos Therapeutics' MDMA prospect for post-traumatic stress disorder at...

AN 2 fifty percents headcount, quits phase 3 trial after information disappoint

.AN2 Rehabs is reassessing its business in response to poor midphase data, promising to lay off half...

Merck pays for $700M for bispecific, spying autoimmune opening and also opportunity to test Amgen in cancer

.Merck &amp Co. is actually paying out $700 million in advance to test Amgen in a blood cancer cells...

Gilead pays J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences almost an FDA choice for its liver health condition medication seladelpar, the...

' All hands on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks may view the business putting together outdoors tents at baseca...

Entero giving up personnel, leaving office and stopping briefly R&ampD

.Bed mattress Liquidators has transformed Entero Rehabs white colored as a sheet. The creditor order...

Exelixis loses ADC after deciding it's no match for Tivdak

.Exelixis is quiting on its cells variable (TF)- targeting antibody-drug conjugate after wrapping up...